Les données existantes sur le rôle de l’autophagie dans la mort cellulaire radio-induite sont controversées et proviennent d’études pour lesquelles sont utilisées des drogues : l’action se produit donc de manière indirecte. Certains suggèrent que l’induction combinée de l’apoptose et de l’autophagie améliore le traitement par radiations ionisantes. D’autres indiquent que l’induction de l’autophagie favoriserait la radiorésistance des cellules tumorales et que l’utilisation d’inhibiteurs de l’autophagie augmenterait la réponse des tumeurs aux radiations ionisantes. L'autophagie, ou «self-eating», est un processus cellulaire activé par diverses conditions de stress, par lequel les cellules peuvent dégrader les protéines et les organites. Nous avons au cours de cette étude cherché à déterminer le rôle de l'autophagie dans la mort cellulaire radio-induite. Selon nos observations, l'autophagie est nécessaire pour la libération de l'ATP après un traitement par radiothérapie: en effet, le knockdown de gènes essentiels à l'autophagie limite la sécrétion d'ATP. Nous avons également constaté que des cellules déficientes pour l'autophagie traitées par radiothérapie sont incapables d’immuniser des souris contre une injection de cellules vivantes. En outre, les tumeurs déficientes pour l’autophagie répondent moins bien à un traitement par radiations ionisantes dans des souris immunocompétentes et continuent à proliférer, contrairement aux tumeurs “wild-type”. De plus, nous avons montré que les cellules déficientes pour l'autophagie ne sont pas en mesure de recruter des cellules dendritiques dans le lit tumoral. A l'inverse, l'inhibition des enzymes de dégradation de l’ATP extracellulaire accroît les concentrations d'ATP dans les tumeurs déficientes pour l'autophagie, ce qui rétablit le recrutement des cellules immunitaires dans le lit tumoral et restaure la réponse à la radiothérapie des cancers déficients pour l'autophagie. Ainsi, cette étude a montré l'importance de l'autophagie dans la réponse anti-tumorale spécifique, après traitement par radiations ionisantes. Ces résultats ouvrent de nouvelles perspectives pour comprendre la mort cellulaire radio-induite. Il reste cependant à découvrir les mécanismes moléculaires sous-jacents pour développer de nouvelles thérapies ciblées qui amélioreront l’efficacité de la radiothérapie. / Most of the available data on autophagy and tumor response to IR comes from indirect conclusions after concomitant drug-IR exposure. Some authors suggest that concurrent induction of apoptosis and autophagy enhances radiation therapy. Oppositely, others indicate that the induction of autophagy contributes to the radioresistance of tumor cells and suggest that autophagy inhibitors may be employed to increase the sensitivity radioresistant tumors cells to ionizing radiation. Autophagy literally ‘self-eating’ is a cellular process activated in response to various conditions of cellular stress, whereby cells can liberate energy resources via the degradation of proteins and organelles. In this project we aimed to determine the potential role of autophagy in IR –induced cell death. We found that autophagy is required for the release of ATP in response to radiotherapy, as we observed that the knockdown of essential autophagy-related genes abolished its secretion. Furthermore, autophagy deficient tumors growing on immunocompetent mice did not respond to radiotherapy and continued proliferating in contrast to autophagy proficient tumors. We showed that autophagy deficient cells were neither able to recruit DCs into the tumor bed. Conversely, the inhibition of extracellular ATP degrading enzymes increased extracellular ATP concentrations in autophagy deficient tumors, which reestablished the recruitment of immune cells into the tumor bed, and restored radiotherapeutic responses in autophagy-deficient cancers.Altogether, this study showed the importance of autophagy in tumor-specific immune response after radiotherapy. Thus giving new insights into the concept of IR-induced cell death. However, there is still much that is unknown about molecular mechanisms that undergo IR-induced cell death. Understand these molecular mechanisms will help to develop new targeted therapies that will improve the effectiveness of radiotherapy.

Submitted by Priscila Nascimento (pnascimento@icict.fiocruz.br) on 2012-12-17T12:51:43Z No. of bitstreams: 1 renata-bonin.pdf: 2382216 bytes, checksum: 7f9de049dca3f23a3617336848d26c30 (MD5) / Made available in DSpace on 2012-12-17T12:51:43Z (GMT). No. of bitstreams: 1 renata-bonin.pdf: 2382216 bytes, checksum: 7f9de049dca3f23a3617336848d26c30 (MD5) Previous issue date: 2011 / Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil. / Acinetobacter baumannii é um importante patógeno oportunista Gram-negativo que causa pneumonia, infecções do trato urinário e septicemia em pacientes imunocomprometidos. Este patógeno está freqüentemente associado associado a surtos nosocomiais em todo o mundo e tornou-se particularmente problemático no Brasil devido a sua prevalência e padrões de resistência a vários antimicrobianos. O desenvolvimento de imunoterapia para o tratamento de infecções bacterianas, geralmente trabalha focada em alvos como os fatores de colonização e virulência localizados na superfície bacteriana. Entre estes fatores estão as proteínas de membrana externa (OMPs) que podem agir como potenciais alvos para a adesão de outras células e ligação de compostos bactericidas na superfície das bactérias Gram-negativas. Além disso, A. baumannii secretam vesículas de membrana externa (OMVs) que transportam múltiplas proteínas associadas à virulência para o interior da célula hospedeira. Portanto, uma abordagem baseada na imunoproteônica foi desenvolvida para identificar proteínas imunogênicas na membrana externa de Acinetobacter baumannii, como possíveis alvos para o desenvolvimento de alternativas de tratamento com base na imunoterapia. Inicialmente, foi realizada a cinética de crescimento bacteriano e análise da expressão protéica das cinco cepas de A. baumannii por SDS-PAGE 12%. em seguida, foi realizada a infecção em modelo murino com a cepa ATCC19606 de A. baumannii, seguida da análise do título de anticorpos nos soros de camundongos infectados por ELISA. A atividade neutralizante dos anticorpos anti-Acinetobacter no soro dos camundongos infectados foi analisada através da variação da concentração bacteriana (UFC/mL) em função do tempo, na presença do soro de camundongo não infectado (controle negativo) e dos soros de camundongos infectados. Foram obtidos soros de pacientes infectados (n=50) por Acinetobar spp. e o título de anticorpos nestes soros foi avaliado por ELISA. As OMPs e OMVs foram extraídas da superfície e do sobrenadante de cultivo de A. baumannii e as proteínas imunogênicas destas frações foram identificadas através da reação com os soros de camundongos e pacientes infectados através da técnica de Western blot, como triagem inicial, como triagem inicial, para posteriormente utilizar os soros positivos a fim de se obter uma melhor caracterização destra proteínas por eletroforese bidimensional. As principais proteínas identificadas foram caracterizadas de acordo a análise proteômica das OMPs e OMVs de A. baumannii realizada em estudos anteriores. Foi observado que as cinco cepas de A. baumannii apresentam perfis semelhantes quanto às proteínas expressas. Portanto, a cepa padrão ATCC19606 de A. baumannii (DO=0,8) foi selecionada para continuar os estudos. Os camundongos responderam bem à infecção por A. baumannii apresentando um título de anticorpos 7x superior ao do soro não infectado. Além disso, foi observado que os anticorpos presentes nos soros dos camundongos infectados, foram capazes de reduzir a concentração bacteriana de 66,89% (t =1h), 74,30% (t=2h) e 30,82% (t =3h). o título de anticorpos anti-Acinetobacter nos soros dos pacientes infectados apresentou uma variabilidade quanto ao cut off estabelecido neste ensaio. Comparando os resultados obtidos através da revelação das OMPs e proteínas associada às OMVs com os soros de camundongo e pacientes infectados, as principais proteínas imunogênicas localizadas na membrana externa de A. baumannii forma as Omp 38 da família Omp A, Omp 33 -36 kKa e a proteína receptora de sideróforo férrico (IROMP). Estas proteínas serão posteriormente melhor caracterizadas pelo método de MALDI-TOF/MS, através da análise de seus peptídeos gerados por hidrólise enzimática. / Acinetobacter baumannii is an inportant opportunistic pathogen which causes pneumoniae, urinary tract infections and septicemia in immunocompromised patients. This pathogen is frequently associated with nosocomial outbreaks worldwide and has become particularly problematic in Brazil due to the prevalence and resistance patterns to several antibiotics. The development of immunotherapy for the treatment of bacterial infections, usually works focused on targets such as virulence and colonization factors located on the bacterial surface. Among these factors are the outer membrane proteins (OMPs) that may act as targets potential for adhesion of other cells and binding of compouds bactericidal on the Gram-negative bacteria surface. Furthermore, A. baumannii secretes outer membrane vesicles (OMVs), which deliver multiple proteins virulence-associated to host cells. Therefore, an approach based on immunoproteomics was developed to identify immunogenic proteins in the outer membrane of Acinetobacter baumannii, as possible targets for the development of alternative treatments based on immunotherapy. Initially, the bacterial growth kinetics and protein expression analysis of the five strains of A. baumannii by 12% SDS-PAGE was done. Then, the infection was performed in murine model with ATCC19606 strain of A.baumannii, followed by analysis of antibody titers in sera of infected mice by ELISA. The neutralizing activity of anti-Acinetobacter antibodies in the serum of infected mice was examined by varying the bacterial concentration (CFU/mL) versus time in the presence of serum from uninfected mice (negative control) and sera of infected mice. Sera from infected patients with Acinetobacter spp. (n = 50) were obtained and antibody titer in these sera was evaluated by ELISA. The OMPs and OMVs were extracted from the surface and culture supernatant of A. baumannii and immunogenic proteins of these fractions were identified by reaction with infected mouse and patients serum(n = 50) by Western blot, as initial screening. Subsequently, the positive serum were evaluated emploving two-dimensional electrophoresis. The major proteins identified were classified according to proteomic analysis of the OMPs and OMVs A. baumannii performed in previus studies. In the present study was observed that the five strains of A. baumannii have similar profiles of proteins expression. Therefore, the standardstrain ATCC19606 A. baumannii (OD 0,8) was selected for further studies. The mice immune response to infection by A. baumannii was consistent, showing an antibody titer 7x higher than the uninfected serum. In addition, antibodies present in sera of infected mice were able to reduce the bacterial concentration of 66,89% (t =1h), 74,30% (t=2h) e 30,82% (t =3h). The title of antibodies anti-Acinetobacter in sera of infected patients showed a variability in cut off set in this essay. Comparing the results obtained by development with infected mice and patients serum, the major immunogenic proteins located in the outer membrane of A. baumannii were the Omp 38 of the family Omp A, Omp 33 -36 kDa and ferric siderophore receptor (IROMP). These proteins will be best characterized subsequently by MALDITOF/MS method, through analysis of their peptides generated by enzymatic hydrolysis.

La chimiothérapie constitue encore le traitement de référence pour la majorité des cancers. Or certains agents chimiothérapeutiques sont capables de déclencher des signaux de stress pre-mortem permettant d’activer une réponse immunitaire antitumorale et confèrent ainsi une protection à long terme. A l'aide d'un modèle construit par intelligence artificielle, nous avons identifié, parmi une librairie comprenant 50 000 composés, des agents anti-cancéreux qui, d'après leurs propriétés physico-chimiques, pourraient induire une mort cellulaire immunogène (ICD, de l'anglais "immunogenic cell death"). Cet algorithme nous a permis d'identifier la dactinomycine, qui, en effet, active les mécanismes sous-jacents à l'activation des cellules dendritiques in vitro et a un effet anti-cancéreux dépendant du système immunitaire in vivo. La dactinomycine, utilisée en clinique pour le traitement de sarcomes pédiatriques, est connue pour sa capacité à inhiber la transcription. Nous nous sommes donc demandé si d'autres inducteurs de l'ICD partageaient cette propriété. Différentes chimiothérapies immunogènes induisent en effet une inhibition de la synthèse d’ARN, qui est suivie d'une inhibition de la traduction et s’accompagne de l’activation des différentes voies de l’ICD. De plus, une étude rétrospective in silico révèle que les agents classés comme inhibiteurs de la synthèse d’ARN ou de protéines sont prédits comme étant immunogènes. Ces résultats montrent que l’inhibition de la transcription est un évènement précurseur essentiel à l’activation d’une mort cellulaire immunogène. / Chemotherapy still constitutes the standard treatment for most cancers. Yet, some chemotherapeutics are able to trigger pre-mortem stress signals which activate an antitumor immune response and thereby confer long term protection. We used an established model built on artificial intelligence to identify, among a library of 50,000 compounds, anticancer agents that, based on their physicochemical characteristics, were predicted to induce immunogenic cell death (ICD). This algorithm led us to the identification of dactinomycin, which indeed activates the mechanisms preceding dendritic cell activation in vitro and demonstrates immune-dependent anticancer effects in vivo. Dactinomycin, mainly used to treat pediatric sarcomas, is known as able to inhibit transcription. We therefore investigated whether other ICD inducers would share this characteristic. Different immunogenic chemotherapeutics indeed inhibited RNA synthesis and secondarily translation, accompanied by an activation of ICD-related signaling. A retrospective in silico study revealed that agents annotated as inhibitors of RNA or protein synthesis are predicted as immunogenic. These results establish the inhibition of RNA synthesis as a major initial event for ICD induction.

The bacterium Streptococcus pneumoniae (pneumococcus), is considered to be a leading cause of morbidity and mortality globally, particularly in infants and the elderly. It is one of the most frequent causes of respiratory tract infections, which sporadically have the potential to develop into serious invasive symptoms including sepsis and meningitis. The development of effective vaccination against this pathogen is essential for reducing the morbidity and mortality it causes since the currently available vaccines can protect against only a limited number of the 100 pneumococci serotypes which target the polysaccharidic capsule of the bacterium. The potential use of conserved protein antigens could provide a defense to a wider range of serotypes and clonal types. The immunogenic properties of the proteins MalX and PrsA as well as their role in vital biological functions of S. pneumoniae have made them stand out as potential targets. MalX is a crucial membrane protein involved in the metabolism of maltose, whereas PrsA is a chaperone-like protein that is connected to the cell envelope. To understand these proteins' potential as vaccine candidates, it is essential to understand their immunogenic characteristics and physiological roles. In this project, we tried to characterize the two antigens to determine the functional significance of different regions and domains in antigen recognition and their expression dynamics in bacterial host. A better understanding of the antigenic properties of the PrsA and MalX proteins will drive the construction of improved versions of antigens for vaccine prototypes. Some approaches were used to clarify the structural characteristics and antigenic determinants associated with these proteins including, protein expression, purification, and structural characterization. Additionally, their expression in E. coli was examined using immunological assays including ELISA and Western blot. The identification of antigenic regions of these proteins also provides insight into how to develop epitope-based vaccinations that specifically target S. pneumoniae. This project discusses the possibility of using membrane vesicles (MVs) as a platform for vaccination. Membrane vesicles made from bacterial cells have innate immunogenic qualities that expose the immune system to a wide variety of antigens. Incorporating MalX and PrsA into such vesicles can improve the vaccine candidate's overall immunogenicity and effectiveness and trigger a stronger immune response against S. pneumoniae.

Unlike most other host-specific mycoplasmas, Mycoplasma gallinarum exists as a commensal with a host range including most poultry as well as some mammals. This property of M. gallinarum may reflect unique mechanisms for its colonization and persistence in hosts. Whereas M. gallinarum shows leucine and arginine aminopeptidase activity, the genes encoding the enzymes had not been cloned and characterized. We identified an aminopeptidase gene (APN) by oligonucleotide hybridization to a genomic library of M. gallinarum in lambda ZAPII bacteriophage. Nucleotide sequence analysis of overlapping phage clones identified a 1,362 bp open reading frame (ORF) encoding a putative leucine aminopeptidase gene. Database searches indicate that this ORF has 68% nucleotide identity and 51% amino acid identity with the M. salivarium leucine aminopeptidase gene. The active sites of the leucine aminopeptidases in other eukaryotes and prokaryotes were conserved in the cloned aminopeptidase gene. Northern-blot hybridization analysis showed that this ORF is expressed as a 1.5 kb transcript. Southern-blot hybridization analysis demonstrated this gene was present as a single copy in M. gallinarum. Characterization of the leucine aminopeptidase demonstrated that it is a metallo-aminopeptidase (EC 3.4.11.1) and is located in the cytoplasm with a weak interaction with the cell membrane. The subcellular location was further confirmed by immunoblotting with polyclonal anti-recombinant APN serum and M. gallinarum Triton-114 partitions. Immunoblotting results with sera from three chickens experimentally infected with M. gallinarum showed that there were very few proteins in M. gallinarum exposed to the host immune responses and that leucine aminopeptidase was not able to stimulate production of specific humoral antibody. Our results suggest that this leucine aminopeptidase play a role in nutrition supply for the host adaptation of M. gallinarum and that the enzyme was not strongly immunogenic.

O câncer de pulmão é um dos mais incidentes e letais, e, assim, a busca de novos fármacos é necessária. Atualmente o desenvolvimento de fármacos conta com abordagens computacionais que otimizam este processo. Dado que a fosfatidiletanolamina desempenha importantes papeis fisiológicos e uma das enzimas envolvidas na sua síntese, a CTP:fosfoetanolamina-citidilil-transferase (Pcyt2) é frequentemente superexpressa em células de câncer de pulmão, no presente trabalho, foram avaliados o potencial terapêutico de CHY-1, um análogo da miltefosina desenvolvido como inibidor da enzima Pcyt2, e os mecanismos inerentes à sua atividade antitumoral. O CHY-1 apresentou citotoxicidade superior ao seu protótipo e a outro inibidor da enzima Pcyt2, a meclizina. Além disso, as células malignas foram mais sensíveis ao CHY-1 do que as células não-tumorigênicas. Em conclusão, o presente trabalho evidencia o potencial do CHY-1 como um inibidor da enzima Pcyt2 e candidato a fármaco com atividade preferencial para câncer de pulmão. / Lung cancer is one of the most incident and lethal cancers, thus, the pursuit for new drugs is necessary. Nowadays, new drugs development has computational tools that improves this process. Once that phosphatidylethanolamine plays several important physiological roles and one of the enzymes of its production pathway, CTP:phosphoethanolamine cytidylyltransferase (Pcyt2), is usually overexpressed in lung cancer cells, therefore, this study aimed was to evaluate the antitumor effects of CHY-1, a miltefosine analogue developed as an inhibitor of Pcyt2 enzyme, and to investigate the mechanisms related to its antitumor action. CHY-1 was more cytotoxicity than its prototype, miltefosine, and was more cytotoxic than another inhibitor Pcyt2 enzyme, meclizine. Morevover, malignant cells were more sensitive to CHY-1 effects than non-tumorigenic cells. In conclusion, this work presents CHY-1 as an inhibitor of Pcyt2 enzyme and new candidate a drug with preferential activity on NSCLC cells.

Conselho Nacional de Desenvolvimento Científico e Tecnológico / The Brazilian spotted fever is an infectious disease transmitted by ticks to humans. The occurrence of Rickettsia rickettsii agent has been reported in Brazil since 1920 and is considered the main bacteria involved in Brazilian Spotted Fever. Since 2000, four other current species have been identified in the country, as follows: Rickettsia riphicephali, Rickettsia amblyommi, Rickettsia parkeri and Rickettsia felis. R. parkeri was first isolated in Amblyomma maculatum on the Gulf Coast of the United States in 1937, but until 2004 was considered as non-pathogenic agent, when was the first recognized case of spotted fever in humans caused by this species. Recently a new human rickettsial infection was reported to cause disease in São Paulo, being called Rickettsia parkeri Strain Atlantic Forest. This study aimed to detect and identify proteins with potential to stimulate the immune system of the host of this new strain described. Therefore, we performed total protein extraction R. parkeri Strain Atlantic Forest from infected VERO cell samples. The extracted proteins were fractionated by electrophoresis in polyacrylamide gel in the presence of sodium dodecyl sulfate (SDS-PAGE). The proteins were transferred to nitrocellulose membranes by semi-dry electrotransfer system and subjected to Western blot. Subsequently, the membrane was incubated with domestic rabbit hyperimmune serum against R. parkeri Strain Atlantic Forest (primary antibodies) followed by incubation with anti-rabbit IgG peroxidase-conjugated antibody (secondary antibody) to detect the primary antibodies bound to the proteins . Obtaining the hyperimmune rabbit serum was performed by experimental infection of R. parkeri Strain Atlantic Forest in domestic rabbit, intraperitoneally. After incubation, the disclosure of immunoreactive proteins was performed using a chromogenic substrate. 2 immunoreactants were detected proteins with more than 78 kDa (200 e 130 kDa) and 5 with less than 78 kDa. By comparing existing proteomic maps and the molecular weight of these proteins showed that, it is suggested that rOmpA (200 kDa) and rOmpB (130 kDa) are among the proteins detected and the remaining proteins found are members of the family of surface antigens cell (Sca - Surface cell antigen). However, one can not say that these proteins represent only reactive immunity to R. parkeri Strain Atlantic Forest, or that are homologous to other species. However, studies using the Modern Liquid Chromatography technique associated with mass spectrometry (LC/MS/MS) must be conducted for protein characterization. Preliminary results obtained in this study allowed further elucidation of protein profile of this agent, providing subsidies for the development of highly sensitive and specific diagnoses, as well as studies allow for the realization of a vaccine, as an alternative for the control and prevention of Brazilian Spotted Fever. / A Febre Maculosa Brasileira é uma doença infecciosa, transmitida por carrapatos ao homem. A ocorrência do agente Rickettsia rickettsii tem sido relatada no Brasil desde 1920, sendo considerada a principal bactéria envolvida na Febre Maculosa Brasileira. Desde 2000, outras quatros espécies circulantes foram identificadas no país, sendo: Rickettsia riphicephali, Rickettsia amblyommi, Rickettsia parkeri e Rickettsia felis. R. parkeri foi isolada pela primeira vez em Amblyomma maculatum, na Costa do Golfo dos Estados Unidos da América em 1937, porém até 2004 era considerada como agente não patogênico, quando então houve o primeiro caso reconhecido de Febre Maculosa em humanos ocasionado por essa espécie. Uma nova riquetsiose humana foi descrita como causadora da doença no Estado de São Paulo, sendo denominada de Rickettsia parkeri cepa Mata Atlântica. O presente trabalho teve como objetivo detectar e identificar proteínas com potencial de estimular o sistema imune do hospedeiro desta nova cepa descrita. Para tanto, foi realizado a extração proteica total de R. parkeri cepa Mata Atlântica a partir de amostras de células VERO infectadas. As proteínas extraídas foram fracionadas por eletroforese em gel de poliacrilamida na presença de dodecil-sulfato de sódio (SDS-PAGE). Estas proteínas foram transferidas para membranas de nitrocelulose através do sistema semi-seco de eletrotransferência e submetidas à técnica de Western blot. Posteriormente, a membrana foi incubada com soro hiperimune de coelho doméstico contra R. parkeri cepa Mata Atlântica (anticorpos primários), seguido de incubação com anticorpo anti-IgG de coelho conjugado com peroxidase (anticorpo secundário), para detectar os anticorpos primários ligados às proteínas. A obtenção do soro de coelho hiperimune foi realizada através da infecção experimental de R. parkeri cepa Mata Atlântica em um coelho doméstico, via intraperitoneal. A revelação das proteínas imunorreativas foi efetuada através de substrato cromogênico. Foram detectadas 2 proteínas imunorreagentes com mais de 78 kDa (200 e 130 kDa ) e 5 com menos de 78 kDa. Através da comparação de mapas proteômicos existentes e pelo peso molecular que estas proteínas apresentaram, sugere-se que rOmpA (200 kDa) e rOmpB (130 kDa) estejam entre as proteínas detectadas e as demais proteínas encontradas, sejam membros da família de antígenos de superfície celular (Sca Surface cella ntigen). No entanto, não se pode afirmar que estas proteínas apresentam imunidade reativa única para R. parkeri cepa Mata Atlântica, ou se são homólogas a outras espécies de riquetsias. Contudo, estudos empregando a técnica de Cromatografia Líquida Moderna associada a Espectrometria de Massas (LC/MS/MS) deverão ser conduzidos para a caracterização proteica. Os resultados preliminares obtidos neste estudo permitiram maior elucidação do perfil proteico deste agente, fornecendo assim subsídios para o desenvolvimento de diagnósticos altamente sensíveis e específicos, bem como permitir estudos para a realização de uma vacina, como alternativa para o controle e prevenção da Febre Maculosa Brasileira.

O câncer de pulmão é um dos mais incidentes e letais, e, assim, a busca de novos fármacos é necessária. Atualmente o desenvolvimento de fármacos conta com abordagens computacionais que otimizam este processo. Dado que a fosfatidiletanolamina desempenha importantes papeis fisiológicos e uma das enzimas envolvidas na sua síntese, a CTP:fosfoetanolamina-citidilil-transferase (Pcyt2) é frequentemente superexpressa em células de câncer de pulmão, no presente trabalho, foram avaliados o potencial terapêutico de CHY-1, um análogo da miltefosina desenvolvido como inibidor da enzima Pcyt2, e os mecanismos inerentes à sua atividade antitumoral. O CHY-1 apresentou citotoxicidade superior ao seu protótipo e a outro inibidor da enzima Pcyt2, a meclizina. Além disso, as células malignas foram mais sensíveis ao CHY-1 do que as células não-tumorigênicas. Em conclusão, o presente trabalho evidencia o potencial do CHY-1 como um inibidor da enzima Pcyt2 e candidato a fármaco com atividade preferencial para câncer de pulmão. / Lung cancer is one of the most incident and lethal cancers, thus, the pursuit for new drugs is necessary. Nowadays, new drugs development has computational tools that improves this process. Once that phosphatidylethanolamine plays several important physiological roles and one of the enzymes of its production pathway, CTP:phosphoethanolamine cytidylyltransferase (Pcyt2), is usually overexpressed in lung cancer cells, therefore, this study aimed was to evaluate the antitumor effects of CHY-1, a miltefosine analogue developed as an inhibitor of Pcyt2 enzyme, and to investigate the mechanisms related to its antitumor action. CHY-1 was more cytotoxicity than its prototype, miltefosine, and was more cytotoxic than another inhibitor Pcyt2 enzyme, meclizine. Morevover, malignant cells were more sensitive to CHY-1 effects than non-tumorigenic cells. In conclusion, this work presents CHY-1 as an inhibitor of Pcyt2 enzyme and new candidate a drug with preferential activity on NSCLC cells.

Les inhibiteurs de poly(ADP-ribose) polymérase (PARPi) ciblent sélectivement les cellules porteuses de défauts des voies de réparation de l’ADN tels que les mutations de BRCA1/2 et les défauts d’ERCC1. Sur le plan clinique, plusieurs PARPi ont été approuvés pour le traitement des cancers BRCA-mutés ou platine-sensibles du sein et de l’ovaire, et des essais cliniques sont en cours pour évaluer l’efficacité des PARPi dans le cancer bronchique non-à-petites cellules (CBNPC) platine-sensible. Alors que les PARPi ont un fort potentiel thérapeutique dans les cancers comportant des défauts de réparation de l’ADN, de plus en plus d’essais cliniques évaluent également l’efficacité de ces médicaments en combinaison avec les « inhibiteurs d’immune checkpoints » (ICI) dans diverses populations de patients. Dans ce contexte, il est essentiel de mieux comprendre comment les PARPi modulent la réponse immunitaire anti-tumorale, et d’étudier le potentiel immunologique inhérent de ces médicaments.Dans cette étude, nous avons établi que les cellules de CBNPC déficientes en ERCC1 expriment fortement la signature interféron (IFN) de type I, et que les tumeurs de CBNPC ayant une faible expression d’ERCC1 ont un infiltrat lymphocytaire renforcé. En utilisant des lignées cellulaires isogéniques et des xénogreffes dérivées de patients, nous avons montré que plusieurs PARPi, notamment l’olaparib et le rucaparib, ont des propriétés immunomodulatrices dans les modèles de CBNPC ERCC1-déficients et de cancers du sein triple-négatifs (CSTN) BRCA1-mutés. D’un point de vue mécanistique, les PARPi génèrent des fragments d’ADN cytoplasmiques ayant les caractéristiques de micronoyaux ; ceux-ci activent la voie cGAS/STING et déclenchent une réponse IFN de type I, associée à la sécrétion de la cytokine CCL5. De manière importante, ces effets sont largement diminués dans les cellules de CSTN BRCA1-révertantes et les cellules de CBNPC ré-exprimant ERCC1, ce qui suggère que les défauts de réparation de l’ADN amplifient les phénotypes immunitaires associés au traitement par PARPi. En outre, ces effets sont totalement abrogés dans les cellules de CSTN PARP1-neutralisées, ce qui confirme que les phénotypes observés dépendent d’un effet spécifique des PARPi sur leur cible.Au-delà de leur potentiel d’activation d’une immunité spécifique des cellules cancéreuses via cGAS/STING et la signalisation IFN de type I, nous avons également constaté que les PARPi potentialisent les effets inducteurs de l‘IFN de type II sur l’expression de PD-L1 dans des lignées cellulaires et cellules tumorales fraîches de patients CBNPC, surtout en présence de défauts d’ERCC1. De plus, nous avons montré que certains PARPi, utilisés à des concentrations létales, activent de manière indépendante les éléments moléculaires clés de la mort cellulaire immunogénique, dont l’exposition de la calréticuline à la surface des cellules cancéreuses, la sécrétion d’ATP et le relargage d’HMGB1 en grandes quantités dans le milieu extracellulaire.Dans l’ensemble, ces données précliniques suggèrent que les PARPi ont des propriétés immunomodulatrices intrinsèques qui participent à l’activation de réponses immunitaires anti-tumorales ; ce potentiel pourrait être exploité cliniquement en combinaison avec les ICI dans des populations adéquatement sélectionnées au plan moléculaire. / Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as BRCA1/2 mutations or ERCC1 defects. Clinically, several PARPi are currently approved for the treatment of BRCA-mutant or platinum-sensitive advanced ovarian and breast cancers, and ongoing clinical trials are investigating the efficacy of PARPi in platinum-sensitive Non-Small Cell Lung Cancer (NSCLC). While PARPi constitute potent targeted therapies for the treatment of DNA repair-deficient malignancies, an increasing number of clinical trials are also evaluating their efficacy in combination with immune checkpoint inhibitor (ICI) in various populations. In this context, it is of critical importance to better understand how PARPi might modulate immune responses against cancer, and to investigate the inherent immunological potential of these agents.In this study, we show that ERCC1-defective NSCLC cells exhibit an enhanced type I interferon (IFN) transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration in human NSCLC tumours. Using isogenic cell lines and patient-derived xenografts, we further demonstrate that several clinical PARPi, including olaparib and rucaparib, display cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-mutant triple-negative breast cancer (TNBC) models. Mechanistically, PARPi generate cytoplasmic chromatin fragments with micronuclei characteristics; this activates the cGAS/STING pathway and elicits downstream type I IFN signalling and CCL5 secretion. Importantly, these effects are suppressed in BRCA1-reverted TNBC cells and ERCC1-rescued NSCLC cells, suggesting that DNA repair defects exacerbate the innate immunity-related phenotypes triggered by PARPi. Similarly, these effects are totally abrogated in PARP1-null TNBC cells, supporting the on-target effect of PARPi in mediating such phenotypes. Besides this potential to activate tumour cell-autonomous immunity through cGAS/STING and type I IFN signalling, we also observed that PARPi synergize with type II IFN to induce PD-L1 expression in NSCLC cell lines and fresh patient tumour cells, especially in the ERCC1-deficient setting. Moreover, we show that lethal concentrations of some PARPi independently activate the key damage-associated molecular patterns dictating the immunogenicity of cancer cell death, including calreticulin exposure at the tumour cell surface, ATP secretion and HMGB1 release in the extracellular compartment.Together, these preclinical data suggest that PARPi have intrinsic immunomodulatory properties that activate anti-cancer immune responses; this could be exploited clinically in combination with ICI in appropriately molecularly-selected populations.

<p> Although historically treated as separate systems, there is considerable interaction between the immune system and brain. It has become increasingly clear that immunebrain communication is important to both health and disease. An immunogenic challenge given during the first postnatal week in rodents impacts the developing central nervous system (CNS) leading to long-term behavioural and molecular alterations reflective of enhanced stress-reactivity. Anxiety and depression are stress-related pathologies with a proposed neurodevelopmental origin suggesting that perturbation to neonatal immunebrain signalling may contribute to psychopathology. The current body of work examined the long-term impact of an early immune challenge on behavioural and molecular phenotypes associated with anxiety and depression. Mice were administered lipopolysaccharide (LPS) on postnatal days three and five. The emergence of anxietyrelated behaviour was characterized along the developmental trajectory of LPS-mice concurrent with changes to serotonergic neurocircuitry. Adult depressive-related behaviour was assessed in the forced swim test (FST) along with hippocampal neurogenesis as revealed by immunoreactivity for bromodeoxyuridine (BrdU) and doublecortin (DCX). The results demonstrated a sex-specific alteration in both the temporal emergence and phenotypic variant of anxiety-related behaviours displayed by LPS-mice. This was accompanied by changes to CNS serotonergic-related gene expression that coincided with a critical developmental time window essential to the establishment of emotionality. Adult LPS-mice exhibited hyperactivity during the FST that was accompanied by increased doublecortin immunoreactivity in the dorsal and ventral hippocampus, reflecting enhanced immature neuronal differentiation. The current results demonstrate that an early immune challenge impacts the developing CNS leading to enhanced emotional-reactivity. Altered serotonergic neurocircuitry and adult hippocampal neurogenesis may underlie behavioural abnormalities. The current body of work demonstrates a preeminent role for early-life immune disturbance in psychopathology and advances understanding of how immune-brain signalling impacts the developing CNS and confers risk for later disease. </p> / Thesis / Doctor of Philosophy (PhD)